As Saudi Arabia seeks to make its healthcare system more cost-efficient, the private equity firm TVM Capital Healthcare is betting $35 million on the Saudi Arabia-based bio-generics provider Boston Oncology Arabia.
ELRIG UK, a leading organization in the drug discovery community, has partnered with The Protein Society (TPS) to host a groundbreaking conference on ‘Protein Sciences in Drug Discovery’.
Once monthly treatment with Novo Nordisk’s antibody treatment reduced annual treated bleeds to zero in 95% previously untreated people with hemophilia A.
Results from a phase 1/2 clinical trial revealed that PolTREG’s regulatory T cell (Treg) therapy, PTG-007, was able to restore insulin secretion in children with type-1 diabetes.
Yesterday (June 24) Novo Nordisk unveiled plans to invest $4.1 billion (approximately €3.8 billion) in a new manufacturing facility in Clayton, North Carolina.
Described by colleagues as an exceptional leader and champion of equity and diversity, this week's woman in science is Maryam Abdul-Kareem, the general counsel of Arcellx.
Thermo Fisher’s new state-of-the-art ultra-cold facility in Bleiswijk, Netherlands, aims to accelerate advanced therapies development by offering a comprehensive range of cold and ultra-cold services.
The Seattle-based company Cyrus Biotechnology has spun out Levitate Bio to offer artificial intelligence (AI)-based protein design software to customers across the biopharma space.
As investors and big pharma pile on developers of antibody-drug conjugates (ADCs), Bright Peak Therapeutics has attracted $90 million based on the promise of a related type of technology called immunoconjugates.
Alvotech of Iceland and STADA Arzneimittel of Germany have extended an existing partnership to co-develop a clinical-stage biosimilar for Prolia and Xgeva, Amgen’s therapies for bone conditions based on the antibody drug denosumab.
Director of cell and gene therapy R&D at Lonza, this week's inspiring female is Inbar who we spoke to about her passion for discovering the future and mentor support sparked her early interest in biology and informed her journey of resiliency.
In spite of their potential to tackle cancer in the long term, CAR-T cell therapies face challenges in terms of pricing, manufacturing and being limited to blood cancer.
Keen to accelerate its drug development, the Japanese pharmaceutical group Kyowa Kirin will pump up to $530 million into building a biologics manufacturing plant in North Carolina, US.
Hikma Pharmaceuticals PLC has made a significant announcement, marking the US launch of Combogesic IV, an intravenous, opioid-free pain relief medication providing a multimodal approach to managing pain in adults.
AbbVie has announced that the Scottish Medicines Consortium (SMC) has approved Tepkinly (epcoritamab) for adults with diffuse large B-cell lymphoma (DLBCL) who have not responded to or have relapsed after at least two prior treatments.
CordenPharma, a global CDMO manufacturing complex drug substances and lipid nanoparticles (LNPs), has signed a partnership agreement with Certest, a Spanish company specializing in drug delivery and API synthesis.
Kyverna Therapeutics has unveiled compelling new data for its CAR T-cell therapy, KYV-101, which may revolutionize the treatment of autoimmune diseases.
Nucleus RadioPharma, a leading player in the development, manufacturing, and supply chain management of radiopharmaceuticals, has announced a significant milestone with the closing of a Series A extension round, featuring a new investment from AstraZeneca.
Alchemab Therapeutics, an antibody discovery company focused on identifying antibodies from individuals resilient to disease, has been awarded a grant of $595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to propel its Parkinson’s...
As the DIA conference in San Diego approaches, Outsourcing Pharma secured an exclusive preview with François Torche, chief product & technology officer and co-founder of CluePoints
As DIA's 60th anniversary at the annual event in San Diego approaches, OSP is excited to bring you insights from Advarra, a leader in advancing clinical research.
Get ready for a big reveal at the DIA conference in San Diego as GiftHealth introduces its latest AI-enabled features designed to revolutionize patient care.
As the anticipation for the 60th DIA annual meeting reaches a fever pitch, eyes should be on Qinecsa, the latest breakthrough in clinical research technology.
At the DIA 2024 Global Annual Meeting, Phastar iwill be proud to join a diverse group of stakeholders from industry, regulatory bodies, academia, and patient communities.
Stella Vnook has founded several biotech companies, including Oral BioLife, a biotechnology firm specializing in pioneering therapies for dental diseases.
In what could be a significant leap for scientific research and biopharmaceuticals, DefiniGEN and Atelerix have unveiled a new collaboration that allows in vitro cell models to be shipped internationally without freezing or cryopreservation.
With a rich background in biochemistry and extensive experience in the pharmaceutical industry, Himanshu Gadgil shares insights into Enzene's journey, its innovative approach to biosimilars.
As the BIO International 2024 trade show approaches, industry insiders anticipate a significant focus on partnership discussions, driven by the pressing financial needs of biotech companies rather than the new BIOSECURE act.
Verona Pharma has revealed its ongoing preparations for the potential launch of ensifentrine in the US market, slated for the third quarter of 2024 pending FDA approval, expected by June 26, 2024.
Thousands of patients in England are set to be enrolled into groundbreaking trials for personalized cancer vaccines through an innovative NHS 'matchmaking' initiative aimed at saving lives.
